Adaptimmune Therapeutics: Q4 Earnings Insights


Adaptimmune Therapeutics ADAP reported its Q4 earnings results on Monday, March 14, 2022 at 07:30 AM.

Here's what investors need to know about the announcement.


Adaptimmune Therapeutics missed estimated earnings by 128.57%, reporting an EPS of $-0.04 versus an estimate of $0.14.

Revenue was down $85.00 thousand from the same period last year.

Past Earnings Performance

Last quarter the company missed on EPS by $0.04 which was followed by a 4.19% increase in the share price the next day.

Here's a look at Adaptimmune Therapeutics's past performance:


Quarter Q3 2021 Q2 2021 Q1 2021 Q4 2020
EPS Estimate -0.26 -0.24 -0.25 -0.23
EPS Actual -0.30 -0.24 -0.24 -0.24
Revenue Estimate 1.37M 1.36M 1.83M 1.98M
Revenue Actual 1.20M 3.10M 434.00K 1.50M

To track all upcoming earnings announcements, click to use Benzinga Earnings Calendar.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsBZI-Recaps